{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:24:02Z","timestamp":1790807042751,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,5,16]],"date-time":"2017-05-16T00:00:00Z","timestamp":1494892800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Familial Cancer"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s10689-017-0002-1","type":"journal-article","created":{"date-parts":[[2017,5,16]],"date-time":"2017-05-16T10:43:13Z","timestamp":1494931393000},"page":"123-128","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Next generation sequencing is informing phenotype: a TP53 example"],"prefix":"10.1007","volume":"17","author":[{"given":"R.","family":"O\u2019Shea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Berkley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Giffney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Farrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"O\u2019Donovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. J.","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,16]]},"reference":[{"issue":"6","key":"2_CR1","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/humu.22559","volume":"35","author":"J Kamihara","year":"2014","unstructured":"Kamihara J, Rana HQ, Garber JE (2014) Germline TP53 mutations and the changing landscape of Li-Fraumeni syndrome. Hum Mutat 35(6):654\u2013662","journal-title":"Hum Mutat"},{"issue":"1","key":"2_CR2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40291-013-0020-0","volume":"17","author":"AD Sorrell","year":"2013","unstructured":"Sorrell AD, Espenschield CR, Culver JO, Weitzel JN (2013) TP53 testing and Li-Fraumeni syndrome: current status of clinical applications and future directions. Mol Diagn Ther 17(1):31\u201347","journal-title":"Mol Diagn Ther"},{"issue":"8","key":"2_CR3","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1200\/JCO.2008.16.6959","volume":"27","author":"KD Gonzalez","year":"2009","unstructured":"Gonzalez KD, Nolter KA, Buzin CH, Gu D, Wen-Fong CY, Nguyen VQ, Han JH, Lowstuter K, Longmate J, Sommer SS, Weitzel JN (2009) Beyond Li Fraumeni syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol 27(8):1250\u20131256","journal-title":"J Clin Oncol"},{"key":"2_CR4","first-page":"5358","volume":"48","author":"FP Li","year":"1988","unstructured":"Li FP, Fraumeni JF, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, Miller RW (1988) A cancer family syndrome in twenty-four kindreds. Cancer Res 48:5358\u20135362","journal-title":"Cancer Res"},{"key":"2_CR5","first-page":"1298","volume":"54","author":"JM Birch","year":"1994","unstructured":"Birch JM, Hartley AL, Tricker KJ, Prosser J, Condie A, Kelsey AM, Harris M, Jones PH, Binchy A, Crowther D, Craft AW, Eden OB, Evans DGR, Thompson E, Mann JR, Martin J, Mitchell ELD, Santibanez-Koref MF (1994) Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res 54:1298\u20131304","journal-title":"Cancer Res"},{"key":"2_CR6","first-page":"101","volume":"25","author":"RA Eeles","year":"1995","unstructured":"Eeles RA (1995) Germline mutations in the TP53 gene. Cancer Surviv 25:101\u2013124","journal-title":"Cancer Surviv"},{"issue":"26","key":"2_CR7","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1200\/JCO.2009.22.7967","volume":"27","author":"J Tinat","year":"2009","unstructured":"Tinat J, Bougeard G, Baert-Desurmont S et al (2009) 2009 version of the Chompret criteria for Li Fraumeni syndrome. J Clin Oncol 27(26):108\u2013109","journal-title":"J Clin Oncol"},{"key":"2_CR8","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1200\/JCO.2014.59.5728","volume":"33","author":"G Bougeard","year":"2015","unstructured":"Bougeard G, Renaux-Petel M, Flaman JM, Charbonnier C, Fermey P, Belotti M, Gauthier-Villars M, Stoppa-Lyonnet D, Consolino E, Brugieres L, Caron O, Benusiglio PR, Bressac de Paillerets B, Bonadona V, Bonaiti-Pellie C, Tinat J, Baert-Desurmont S, Frebourg T (2015) Revisiting Li-Fraumeni syndrome from TP53 carriers. J Clin Oncol 33:2345\u20132352","journal-title":"J Clin Oncol"},{"key":"2_CR9","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1054\/bjoc.2000.1167","volume":"82","author":"A Chrompret","year":"2000","unstructured":"Chrompret A, Brugieres L, Ronsin M et al (2000) P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer 82:1932\u20131937","journal-title":"Br J Cancer"},{"key":"2_CR10","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1136\/jmg.2008.058958","volume":"46","author":"KD Gonzalez","year":"2009","unstructured":"Gonzalez KD, Buzin CH, Noltner KA, Gu D, Li W, Malkin D, Sommer SS (2009) High frequency of de novo mutations in Li-Fraumeni syndrome. J Med Genet 46:689\u2013693","journal-title":"J Med Genet"},{"key":"2_CR11","volume-title":"GeneReviews","author":"K Schneider","year":"1993","unstructured":"Schneider K, Garber J (1993) Li-Fraumeni syndrome. In: Pagon RA, Bird TD, Dolan CR, Stephens K, Adam MP (eds) GeneReviews, University of Washington, Seattle, Seattle"},{"key":"2_CR12","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/humu.10081","volume":"19","author":"M Olivier","year":"2002","unstructured":"Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P (2002) The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 19:607\u2013614","journal-title":"Hum Mutat"},{"key":"2_CR13","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/humu.10185","volume":"21","author":"JM Varley","year":"2003","unstructured":"Varley JM (2003) Germline TP53 mutations and Li-Fraumeni syndrome. Hum Mutat 21:313\u2013320","journal-title":"Hum Mutat"},{"key":"2_CR14","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1038\/sj.bjc.6605606","volume":"102","author":"DGR Evans","year":"2010","unstructured":"Evans DGR, Moran A, Hartley R, Dawson J, Bulman B, Knox F, Howell A, Lalloo F (2010) Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA I\/BRCA2\/TP53 status. Br J Cancer 102:1091\u20131098","journal-title":"Br J Cancer"},{"key":"2_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s10689-012-9557-z","author":"JM McCuaig","year":"2012","unstructured":"McCuaig JM, Armel SR, Novokmet A et al (2012) Routine TP53 testing for breast cancer under age 30: ready for prime time? Fam Cancer. doi:\n10.1007\/s10689-012-9557-z","journal-title":"Fam Cancer"},{"key":"2_CR16","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.ejca.2005.11.032","volume":"42","author":"F Lalloo","year":"2006","unstructured":"Lalloo F, Varley J, Moran A, Ellis D, O\u2019Dair L, Pharoah P, Antoniou A, Hartley R, Shenton A, Seal S, Bulman B, Howell A et al (2006) BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. Eur J Cancer 42:1143\u20131150","journal-title":"Eur J Cancer"},{"key":"2_CR17","doi-asserted-by":"crossref","first-page":"4795","DOI":"10.1158\/0008-5472.CAN-09-0851","volume":"70","author":"J Mouchawar","year":"2010","unstructured":"Mouchawar J, Korch C, Byers T, Pitts TM, Li E, McCredie MR, Giles GG, Hopper JL, Southey MC (2010) Population-based estimate of the contribution of TP53 mutations to subgroups of early-onset breast cancer: Australian Breast Cancer Family Study. Cancer Res 70:4795\u20134800","journal-title":"Cancer Res"},{"key":"2_CR18","doi-asserted-by":"crossref","first-page":"563e7","DOI":"10.1007\/s10689-009-9287-z","volume":"8","author":"OM Ginsburg","year":"2009","unstructured":"Ginsburg OM, Akbari MR, Aziz Z, Young R, Lynch H, Ghadirian P, Robidoux A, Londono J, Vasquez G, Gomes M, Costa MM, Dimitrakakis C, Gutierrez G, Pilarski R, Royer R, Narod SA (2009) The prevalence of germ-line TP53 mutations in women diagnosed with breast cancer before age 30. Fam Cancer 8:563e7","journal-title":"Fam Cancer"},{"key":"2_CR19","first-page":"3234e6","volume":"52","author":"AL Borresen","year":"1992","unstructured":"Borresen AL, Andersen TI, Garber J, Barbier-Piraux N, Thorlacius S, Eyfjord J, Ottestad L, Smith-Sorensen B, Hovig E, Malkin D, et al (1992). Screening for germ line TP53 mutations in breast cancer patients. Cancer Res 52:3234e6","journal-title":"Cancer Res"},{"key":"2_CR20","first-page":"5291e8","volume":"52","author":"C Coles","year":"1992","unstructured":"Coles C, Condie A, Chetty U, Steel CM, Evans HJ, Prosser J. (1992) p53 mutations in breast cancer. Cancer Res 52:5291e8","journal-title":"Cancer Res"},{"key":"2_CR21","first-page":"2984e6","volume":"52","author":"D Sidransky","year":"1992","unstructured":"Sidransky D, Tokino T, Helzlsouer K, Zehnbauer B, Rausch G, Shelton B, Prestigiacomo L, Vogelstein B, Davidson N (1992) Inherited p53 gene mutations in breast cancer. Cancer Research 52:2984e6","journal-title":"Cancer Research"},{"key":"2_CR22","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1136\/jmg.2009.073429","volume":"47","author":"MWG Ruijis","year":"2010","unstructured":"Ruijis MWG, Verhoef S, Rookus MA, Pruntel R, van der Hout AH, Hogervorst F, Kluijt I, Sijmons RH, Aalfs CM, Wagner A, Ausems M, Hoogerbrugge N, van Asperen CJ, Gomez Garcia E, Meijers-Heijboer H, ten Kate LP, Menko FH, van\u2019t Veer LJ (2010) TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. J Med Genet 47:421\u2013428","journal-title":"J Med Genet"},{"key":"2_CR23","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1053\/j.gastro.2005.10.014","volume":"130","author":"P Wong","year":"2006","unstructured":"Wong P, Verselis SJ, Garber JE, Schneider K, DiGianni L, Stockwell DH, Li FP, Syngal S (2006) Prevalence of early onset colorectal cancer in 397 patients with classic Li-Fraumeni syndrome. Gastroenterology 130:73\u201379","journal-title":"Gastroenterology"},{"issue":"3","key":"2_CR24","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1007\/s10549-012-1993-9","volume":"133","author":"S Masciari","year":"2012","unstructured":"Masciari S, Dillon DA, Rath M et al (2012) Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort. Breast Cancer Res Treat 133(3):2984\u20132986","journal-title":"Breast Cancer Res Treat"},{"key":"2_CR25","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10549-012-2375-z","volume":"139","author":"MG Rath","year":"2013","unstructured":"Rath MG, Masciari S, Gelman R, Miron A, Miron P, Foley K, Richardson AL, Krop IE, Verselis SJ, Dillon DA, Garber JE (2013) Prevalence of germline TP53 mutations in HER2+ breast cancer patients. Breast Cancer Res Treat 139:193\u2013198.","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"2_CR26","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/cncr.26377","volume":"118","author":"A Melhem-Bertrandt","year":"2012","unstructured":"Melhem-Bertrandt A, Bojadzieva J, Ready KJ et al (2012) Early onset HER2-positive breast cancer is associated with germline TP53 mutations. Cancer 118(4):908\u2013913","journal-title":"Cancer"},{"key":"2_CR27","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/1471-2407-12-237","volume":"12","author":"AG Silva","year":"2012","unstructured":"Silva AG, Ewald IP, Sapienza M, Pinheiro M, Peixoto A, de Nobrega AF, Carraro DM, Teixeira MR, Ashton-Prolla P, Achatz MI, Rosenberg C, Krepischi AC (2012) Li-Fraumeni-like syndrome associated with a large BRCA1 intragenic deletion. BMC Cancer 12:237","journal-title":"BMC Cancer"},{"key":"2_CR28","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1200\/JCO.2012.46.9403","volume":"31","author":"SM Domchek","year":"2013","unstructured":"Domchek SM, Bradbury A, Garber JE, Offit K, Robson ME (2013) Multiplex genetic testing for cancer susceptibility: out on the high wire without a net? J Clin Oncol 31:1267\u20131270","journal-title":"J Clin Oncol"},{"issue":"8","key":"2_CR29","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/pon.1352","volume":"17","author":"SK Peterson","year":"2008","unstructured":"Peterson SK, Pentz RD, Marani SK et al (2008) Psychological functioning in persons considering genetic counseling and testing for Li-Fraumeni syndrome. Psychooncology 17(8):783\u2013789","journal-title":"Psychooncology"},{"issue":"18","key":"2_CR30","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1200\/JCO.2009.27.2112","volume":"28","author":"CR Lammens","year":"2010","unstructured":"Lammens CR, Aaronson NK, Wagner A et al (2010) Genetic testing in Li-Fraumeni syndrome: uptake and psychosocial consequences. J Clin Oncol 28(18):3008\u20133014","journal-title":"J Clin Oncol"},{"issue":"6","key":"2_CR31","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/pon.1951","volume":"20","author":"CR Lammens","year":"2011","unstructured":"Lammens CR, Bleiker EM, Verhoef S et al (2011) Distress in partners of individuals diagnosed with or at high risk of developing tumors due to rare hereditary cancer syndromes. Psychooncology 20(6):631\u2013638","journal-title":"Psychooncology"},{"key":"2_CR32","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1001\/jama.299.11.1315","volume":"299","author":"S Masciari","year":"2008","unstructured":"Masciari S, Van den Abbeele AD, Diller LR, Rastarhuyeva I, Yap J, Schneider K, Digianni L, Li FP, Fraumeni JF Jr, Syngal S, Garber JE (2008) F18-fluorodeoxyglucosepositron emission tomography\/computed tomography screening in Li-Fraumeni syndrome. JAMA 299:1315\u20131319","journal-title":"JAMA"},{"issue":"6","key":"2_CR33","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1470-2045(11)70119-X","volume":"12","author":"A Villani","year":"2011","unstructured":"Villani A, Tabori U, Schiffman J et al (2011) Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. Lancet Oncol 12(6):559\u2013567","journal-title":"Lancet Oncol"}],"container-title":["Familial Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10689-017-0002-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-017-0002-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-017-0002-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,16]],"date-time":"2018-01-16T10:07:17Z","timestamp":1516097237000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10689-017-0002-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,16]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["2"],"URL":"https:\/\/doi.org\/10.1007\/s10689-017-0002-1","relation":{},"ISSN":["1389-9600","1573-7292"],"issn-type":[{"value":"1389-9600","type":"print"},{"value":"1573-7292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,16]]}}}